Novo Nordisk CEO Looks Beyond Weight Loss to Longevity and Aesthetics

Novo Nordisk's CEO says the company’s blockbuster obesity drugs could ultimately pull it into increasingly buzzy areas of healthcare, from longevity research to aesthetic medicine.